LAWRENCEVILLE, N.J.--(BUSINESS WIRE)--Asana BioSciences announced today positive topline results from a Phase 1b study evaluating the treatment of pruritus associated with atopic dermatitis ...

Nat Clin Pract Neurol. 2008;4(3):159-169. Drug Primary clinical use Protective effect during administration in animal models? Effects of withdrawal in EAE Clinical study Phenytoin Treatment of ...

WATERTOWN, Mass.--(BUSINESS WIRE)--Nocion Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel small molecule charged sodium channel blockers called “nocions”, that ...

PHILADELPHIA -- An oral, non-addictive sodium channel blocker safely relieved moderate-to-severe acute pain following surgery, according to phase III data that could support regulatory approval.

South Korea’s SK Biopharmaceuticals Co. Ltd. and Shanghai-based Ignis Therapeutic Co. Ltd. signed a ₩804 billion (US$58 million) licensing deal on April 18, granting the latter global rights to a ...

Site 1 sodium channel blockers such as tetrodotoxin and saxitoxin are small-molecule drugs with powerful local anesthetic properties. They provide pain relief without toxic effects on local nerves and ...

Inspired by the natural bonding between a class of potent local anesthetics called site-1 sodium channel blockers (S1SCBs) and peptide sequences on the sodium channel in the nerve cell membrane, ...

A new study on live tissue cells is the first to reveal how channels that allow sodium to enter into breast cancer cells enable tumours to grow and spread. The discovery adds to evidence which ...